Company intelligence / Profile preview

QureTech Bio

Ownership: Private
Development stage: Preclinical

Overview

QureTech Bio is developing a new class of antibiotics called GmPcides that are bactericidal against Gram-positive bacteria, including drug-resistant strains such as MRSA and VRE. No resistance development has been detected in vitro or in clinical isolates. The company also has a drug candidate that has received preliminary approval for a patent application in the US for treating tuberculosis.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

GmPcides

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on QureTech Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QureTech Bio.

Explore the full profile